NSE ScannerHospitals & Diagnostics · Medical/Nursing Services · NSE: DRAGARWQ · data 2026-10-31
Dr. Agarwal'S Eye Hospital Limited
In plain words
Price: 12.2% below its 52-week high of ₹6,059.7.
Delivery: 72.4% of traded shares were kept for delivery over the last 10 sessions, against 66.1% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹497 cr |
| Net profit (last 12 months) | ₹76 cr |
| Sales growth, 3 years (yearly) | 20.7% |
| Profit growth, 3 years (yearly) | 23.8% |
At a glance
P/E 33.5, dividend yield 0.1%. Price relative to earnings and book value (low is cheaper, not better).
ROE 25.2%, ROCE 17.4%, operating margin 21.1%: how much profit it earns on the money it uses.
Debt/equity 0.94, Profit growth 23.8% and sales growth 20.7% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- High return on equity (25.2%).
- Healthy operating margin (21.1%).
- Profit grew 23.8% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
19/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 14/30: Delivery 80.0% over the last 20 sessions vs 68.9% in the 40 before (1.16x); shares delivered per day 1.19x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend
- 2 Sept 26Dividend Dividend ₹4 (ex-date) +0.6% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Common questions
Is Dr. Agarwal'S Eye Hospital Limited debt-free?
Its latest reported debt-to-equity ratio is 0.94.
What is Dr. Agarwal'S Eye Hospital Limited's P/E ratio?
About 33.5, based on the last 12 months' earnings and a price of ₹5,317.5 (data 2026-10-31).
What is the 52-week high and low of Dr. Agarwal'S Eye Hospital Limited?
The 52-week high is ₹6,059.7 and the 52-week low is ₹4,600.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Dr. Agarwal'S Eye Hospital Limited | ₹5,317.5 | ₹2,552 cr | 33.5 | — | 25.2% | 17.4% | 0.94 | +13.1% |
| Nephrocare Health Services Limited | ₹614.55 | ₹6,194 cr | — | — | 9% | 14.6% | 0.07 | +25.4% |
| Jeena Sikho Lifecare Limited | ₹334.45 | ₹4,149 cr | 17.6 | — | 60% | 62.7% | 0.27 | -54.9% |
| Suraksha Diagnostic Ltd. | ₹316.35 | ₹1,653 cr | 46 | — | 14.1% | 15.1% | 0.53 | -2.1% |
| Krsnaa Diagnostics Limited | ₹503.75 | ₹1,635 cr | 17 | — | 10.9% | 9.8% | 0.55 | -36.3% |
| Laxmi Dental Ltd. | ₹177.58 | ₹978 cr | 31.6 | — | 12.8% | 11.4% | 0.05 | -43.3% |
Compare DRAGARWQ with NEPHROPLUS in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open DRAGARWQ in NSE Scanner →